U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07547787) titled 'A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)' on April 17.
Brief Summary: This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Study Start Date: Dec. 26, 2024
Study Type: OBSERVATIONAL
Condition:
Locally Advanced Unresectable or Metastatic Gastric Cancer
Recruitment Status: RECRUITING
Sponsor: Akeso
Disclaimer: Curated by HT Syndication....